![]() ![]() This novel mechanism of action is designed to support safer and more predictable bone formation compared to commercially available bone growth factors. i-FACTOR Peptide Enhanced Bone Graft is the only biologic bone graft in orthopedics that incorporates a small peptide as an attachment factor to stimulate the natural bone healing process. i-FACTOR Peptide Enhanced Bone Graft must be used inside an allograft bone ring and with supplemental anterior plate fixation.Ĭerapedics is an ortho-biologics company focused on developing and commercializing its proprietary small peptide (P-15) technology platform. In the United States, i-FACTOR Peptide Enhanced Bone Graft is indicated for use in skeletally mature patients for reconstruction of a degenerated cervical disc at one level from C3-C4 to C6-C7 following single-level discectomy for intractable radiculopathy (arm pain and/or a neurological deficit), with or without neck pain, or myelopathy due to a single-level abnormality localized to the disc space, and corresponding to at least one of the following conditions confirmed by radiographic imaging (CT, MRI, X-rays): herniated nucleus pulposus, spondylosis (defined by the presence of osteophytes), and/or visible loss of disc height as compared to adjacent levels, after failure of at least 6 weeks of conservative treatment. i-FACTOR+ Matrix is the same technology as the P15-L investigational material in the IDE," said Jeffrey Marx, Ph.D., President and Chief Operating Officer of Cerapedics.ĬAUTION: In the United States, P-15L Bone Graft (i-FACTOR+ Matrix) is an Investigational Product limited by Federal Law to investigational use only. He provides leadership of KUBRA’s delivery of services and operation, ensuring exceptional client experience across KUBRA’s enterprise solution platform. "In addition to the commercial launch in Canada, the latest i-FACTOR+ MATRIX generation is currently being studied in our FDA IDE study, ASPIRE, targeting lumbar fusions (TLIF), as previously announced. Tony is charged with developing and executing KUBRA’s vision and strategic growth through technology and solution innovation. Food and Drug Administration (FDA) premarket approval (PMA) application in 2015 only for use in single-level anterior cervical fusion procedures. i-FACTOR Peptide Enhanced Bone Graft is the only biologic bone graft in orthopedics that incorporates a small peptide as an attachment factor to stimulate the. In the United States, i-FACTOR Peptide Enhanced Bone Graft was approved via a U.S. Cerapedics initial P-15 technology product, i-FACTOR Peptide Enhanced Bone Graft, was approved in the European Union in 2008 and Australia in 2010 for use in the repair of bony voids or defects in orthopedic applications throughout the skeletal system (i.e., the spine and extremities). I-FACTOR+ MATRIX utilizes a small proprietary peptide (P-15) technology developed by Cerapedics to support bone growth through cell attraction, attachment, and activation. " Canada will be the first market offering the i-FACTOR+ MATRIX product, which leverages the clinically proven P-15 osteogenic cell-binding peptide combined with a collagen carrier for optimized handling." "We are excited to announce that i-FACTOR+ Matrix is now fully available in Canada through our distributor Surgi-One and can be used in both spine and general orthopedic applications," said Glen Kashuba, Chief Executive Officer of Cerapedics. 5, 2020 /PRNewswire/ - Cerapedics, a private ortho-biologics company, today announced the full commercial availability of i-FACTOR+ MATRIX for surgical implantation in Canada. Architecture & Interior Design, Automobile, Defence & Aerospace, FMCG, Retail, Engineering & Construction, Consumer Electronics & Appliances, Aviation. The most important element in my view is there a shared vision of how SME lending will really look like in the years to come and how major lenders will be able to effectively service the low end of the market by introducing reliable technologies.Canada will be the first commercial market to launch i-FACTOR ®+ Matrix The management team is extremely skilled and experienced in scaling businesses which they have done in the region for a number of years successfully. Enabling and improved capital allocation in matching. Second, their envision lending as a future marketplace where different lenders will be able to bid for the right clients with the right credit scoring. Their approach is twofold:įirst, they have designed a robust technology solution sitting in the backend of lending organisations improving the KYC AML elements and processes thus Improving the cost efficiency for lending to SMEs. Flavia Richardson recommended iFactor where Sebastian works ĬCO Advisory Group, Chartered Accountant addresses the major challenges in SME finance.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |